gefitinib
Showing 1 - 25 of 576
Solid Tumor Trial in Seoul (Gefitinib)
Completed
- Solid Tumor
- Gefitinib
-
Seoul, Korea, Republic ofSamsung Medical Center
Jun 13, 2022
NSCLC, Brain Metastases, EGFR Mutation Trial in Guangzhou (Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy)
Recruiting
- Non-small Cell Lung Cancer
- +2 more
- Gefitinib and Pemetrexed/platinum
- Gefitinib mono-therapy
-
Guangzhou, Guangdong, ChinaSun Yat-sen University of Cancer Center
Feb 19, 2022
Lung Cancer Trial in Boston (EGF816, Gefitinib)
Active, not recruiting
- Lung Cancer
- EGF816
- Gefitinib
-
Boston, MassachusettsMassachusetts General Hospital
Jan 21, 2022
A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib
Recruiting
- Non-small Cell Lung Cancer (NSCLC)
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Oct 25, 2022
Ovarian Cancer, Peritoneal Tumors, Fallopian Tube Cancer Trial in Houston (Topotecan, Gefitinib)
Completed
- Ovarian Cancer
- +2 more
- Topotecan
- Gefitinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Jan 11, 2022
Erlotinib/Gefitinib Combined With Bevacizumab in Advanced
Recruiting
- Non Small Cell Lung Cancer
- Erlotinib/Gefitinib combined with Bevacizumab
-
Changsha, Hunan, ChinaHunan Provincal Tumor Hospital
Mar 1, 2022
NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- +2 more
- Nintedanib, gefitinib, erlotinib, afatinib
- (no location specified)
Oct 2, 2023
Gefitinib Long-term Survivor Study
Terminated
- EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
-
Beijing, Beijing, China
- +13 more
Mar 9, 2022
Cancer Medicines in Metastatic Non-small Cell Lung Cancer in
Not yet recruiting
- Non-Small Cell Lung Cancer
- lorlatinib
- +17 more
-
Oslo, NorwayPfizer Norway
Apr 17, 2023
NSCLC Trial in Singapore (Gefitinib)
Completed
- Non-small Cell Lung Cancer
- Gefitinib
-
Singapore, SingaporeNational Cancer Centre
May 31, 2021
NSCLC With EGFR-Activating Mutations Trial in Worldwide (Dacomitinib (PF-00299804), Gefitinib)
Completed
- Non-small Cell Lung Cancer With EGFR-Activating Mutations
- Dacomitinib (PF-00299804)
- Gefitinib
-
Beijing, China
- +51 more
Feb 10, 2022
Non Small Cell Lung Cancer Trial in Beijing (HS-10296, Gefitinib)
Active, not recruiting
- Non Small Cell Lung Cancer
- HS-10296
- Gefitinib
-
Beijing, ChinaBeijing Cancer Hospital
Jan 19, 2022
NSCLC Trial in Worldwide (Tepotinib, Gefitinib, Pemetrexed)
EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)
Active, not recruiting
- EGFR-mutant Non-small Cell Lung Cancer
- EGF816
- +5 more
-
Toronto, Ontario, Canada
- +10 more
Dec 5, 2022
Non-small Cell Lung Carcinoma Trial (Pembrolizumab, Paclitaxel, Carboplatin)
Completed
- Non-small Cell Lung Carcinoma
- Pembrolizumab
- +7 more
- (no location specified)
Oct 13, 2022
Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)
Recruiting
- Rare Tumor
- Refractory Tumor
- Gefitinib
- +11 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Feb 16, 2022
Hepatocellular Carcinoma, Molecular Targeted Therapy Trial in Shanghai (Lenvatinib and Gefitinib)
Unknown status
- Hepatocellular Carcinoma
- Molecular Targeted Therapy
- Lenvatinib and Gefitinib
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiaotong University
Jan 13, 2021
NSCLC Trial in Guangzhou (Apatinib Mesylate, Gefitinib)
Recruiting
- NSCLC
- Apatinib Mesylate, Gefitinib
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Univercity Cancer Center
Jan 7, 2021
Non-small-cell Lung Cancer Trial in Shanghai (gefitinib combined with chemo, gefitinib combined with apatinib, gefitinib single
Unknown status
- Non-small-cell Lung Cancer
- gefitinib combined with chemotherapy
- +2 more
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital;
Jul 31, 2020
Advanced NSCLC With EGFR Mutation Trial in Zhengzhou (S-1 plus Gefitinib, Gefitinib)
Unknown status
- Advanced NSCLC With EGFR Mutation
- S-1 plus Gefitinib
- Gefitinib
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jul 8, 2020
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma Trial in Philadelphia (drug, radiation, other)
Completed
- Adult Giant Cell Glioblastoma
- +2 more
- gefitinib
- +2 more
-
Philadelphia, PennsylvaniaRadiation Therapy Oncology Group
Oct 29, 2020
Advanced Solid Tumors Which Are cMET-dependent Trial in Worldwide (Capmatinib, Nazartinib, Gefitinib)
Recruiting
- Advanced Solid Tumors Which Are cMET-dependent
- Capmatinib
- +3 more
-
Boston, Massachusetts
- +12 more
Jan 27, 2023